Skip Navigation
National Cancer Institute U.S. National Institutes of Health www.cancer.gov
Sections
You are here: Home Community Dialog Questions Submitted Online question_1296185035
Back to Questions

Question ID: WS-17
Submitted by: John Baron
January 27, 2011

Does DFMO really seriously impede colorectal carcinogenesis, as suggested in a recent clinical trial with an adenoma endpoint? Does this imply that polyamines are central to the development of neoplasia in the large bowel? Meysekens et al reported that DFMO + sulindac reduced the risk of all adenomas by about 70%, and reduced the risk of advanced adenomas by more than 90%. These findings are substantially more marked than those of any other chemopreventive agent. Since DFMO is a designer drug that inhibits ornithine decarboxylase, the first step in the synthesis of polyamines, these results imply that polyamines may be central to colorectal carcinogenesis.

This question has not yet been evaluated by users

Comments

Download Plugins: Download Plugin Adobe Acrobat Reader   Download Plugin Adobe Flash Player   Download Plugin Microsoft Word Viewer   Download Plugin Microsoft Excel Viewer   Download Plugin Microsoft PowerPoint Viewer   Download Plugin Real Player   Download Plugin Windows Media Player   Download Plugin Quicktime Player   Download Plugin WinZip
National Cancer Institute Department of Health and Human Services National Institutes of Health USA.gov